Clinical stage focus Target the biopharma client with a strong focus on immuno-oncology, clinical-stage programs, and novel pathways such as TIGIT/CD226 and the adenosine axis. Position iTeos as a partner for translational science support, larger-scale clinical progression, and combination therapy exploration.

Leadership and continuity Recent leadership changes include the departure of the President & CEO and a new CEO appointment from the board, alongside a Chief Scientific Officer transition. Opportunities exist to engage during leadership realignment for strategic partnerships, licensing discussions, and ongoing pipeline stewardship.

Strategic divestment moves Note the company’s decision to cease investing in the anti-TIGIT antibody belrestotug and the 2025 acquisition events involving Concentra Biosciences. This signals openness to strategic collaborations, asset divestiture considerations, and potential partnership or licensing discussions for pipeline assets.

Global presence With headquarters in the US and a research center in Belgium, iTeos maintains an international footprint. This offers co-development, joint research, and cross-border manufacturing or clinical trial opportunities that can align with global CROs, contract development, and supply chain partners.

Financials and scale Funding level at hundreds of millions and modest revenue range indicate a pipeline-heavy, growth-stage profile. Tailor outreach to secure milestone-based collaborations, strategic investments, or co-development deals that align with the company’s clinical-stage emphasis and resource needs.